Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Despite the lack of an overall survival benefit the Seal study gives Karyopharm enough to file for Xpovio’s first solid tumour use.
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.
The first look at Turning Point’s TPX-0022 shows signs of activity beyond cMet inhibitors’ proven use in lung cancer.
Mirati’s Kras inhibitor looks better than Amgen’s on efficacy, but toxicity worries prevent a knockout punch.
November 6 is the day that could make or break Biogen.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.